Results from a retrospective study based on a claims database of U.S. patients with pulmonary embolism indicated that physicians are failing to recognize and diagnose thousands of cases of a serious lung disease, chronic thromboembolic pulmonary hypertension (CTEPH). The study, “Monitoring for Pulmonary Hypertension Following Pulmonary Embolism: The INFORM…
The following are the 5 different classes of pulmonary hypertension. For a detailed overview of each class, click on the link: Arterial PH: Pulmonary arterial hypertension (PAH) involves abnormally high blood pressure (hypertension) in the pulmonary artery. Venous PH: Pulmonary venous hypertension (PVH) differs from…
German researchers evaluating a possible new biomarker for pulmonary arterial hypertension (PAH) found that the molecule, known as chemokine CXC ligand 13 (CXCL13), was higher in the blood serum and lung tissue of people with PAH — suggesting a pathogenic role but one short of serving as a disease marker. The report,…
Recent advances made, and insights gained, in clinical and preclinical research into pulmonary hypertension were highlighted in a Clinical Year in Review article published in the journal European Respiratory Review. The article, “Pulmonary hypertension,” offers hope that pulmonary hypertension might become a well-managed, and potentially even…
German President Joachim Gauck has awarded the 2015 Deutscher Zukunftspreis, which honors innovation in science and technology, to a pulmonary hypertension (PH) research team that discovered and developed a drug effective in the treatment of two serious types of the disease. The winning team — led by Professor Ardeschir Ghofrani from the University Clinic…
[vc_row][vc_column][vc_column_text]Pulmonary hypertension (PH) is a rare, life-threatening condition characterized by high blood pressure in the lungs and measured according to a resting mean pulmonary arterial pressure of 25 mmHg or greater at right heart catheterization. The disease is associated with damage to the pulmonary arteries, which are responsible for transporting blood…
Pulmonary hypertension (PH) is a chronic and progressive disease associated with high blood pressure in the blood vessels, known as the pulmonary arteries, that supply the lungs. It is very difficult to detect and diagnose PH in routine physical exams, given that its symptoms can develop over a…
Pulmonary hypertension (PH) is a rare lung disease characterized by high blood pressure in the pulmonary arteries, which deliver blood from the heart to the lungs. The high pressure causes the heart to work harder to pump blood. This strain can lead to the heart becoming larger and weaker, and…
[vc_row][vc_column][vc_column_text]Pulmonary hypertension (PH) is a severe disease diagnosed when the arteries responsible for transporting blood from the heart to the lungs become constricted. Under normal circumstances, blood is supposed to gather oxygen from the lungs and distribute it to the organs, muscles and body tissue. However, due to the disease, normal blood flow…
Pulmonary hypertension (PH) is a rare disease characterized by abnormally high blood pressure in the pulmonary arteries, which are responsible for transporting blood from the heart to the lungs. As a result of blood vessel narrowing, the heart’s right ventricle needs to work harder to pump blood, becoming enlarged…
Pulmonary hypertension is a chronic and progressive disease characterized by high blood pressure in the pulmonary arteries, the blood vessels of the lungs. There are many potential causes of the disease that, along with how early the disease is diagnosed and when treatment…
Ventavis (iloprost) is an approved therapy for improving the exercise capacity of people with pulmonary arterial hypertension (PAH), and potentially delaying or reducing the worsening of the disease. Ventavis was developed by Schering AG but is now marketed by Bayer in Europe…
Get regular updates to your inbox.